Report topline results from the XEN007 Phase 2 proof-of-concept study
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expects that topline results from a larger data set will be available by the middle of 2021.”
What we found
Evidence strength A What the grades mean
The company failed to report the XEN007 topline results by the middle of 2021, instead pushing the anticipated reporting date to the end of 2021 in an August 2021 filing.
-
A Xenon Pharmaceuticals Inc. 10-Q filed 2021-08-11
“Additional results from a larger data set are anticipated by the end of this year, which will inform our decision regarding the future development of XEN007.” ✓ confirmed on the page
Market reaction: the shares moved +9.1% against the S&P 500 over the three sessions around the disclosure (10 Aug 2021 to 13 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- XEN007 Phase 2 proof-of-concept study topline results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Xenon Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-XENE-022087 · Corrections policy